Previous 10 | Next 10 |
2024-03-08 09:01:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips AerSale (NASDAQ: ASLE ) stock is down on Friday after releasing its earnings report for the fourth quarter of 2023. The bad news for ASLE stockholders starts with the aftermarke...
2024-03-08 08:37:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Affimed (NASDAQ: AFMD ) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company’s shares to undergo a reverse split later today ...
2024-03-06 06:47:44 ET More on Affimed Affimed CEO Adi Hoess to step down, Andreas Harstrick appointed interim CEO Affimed sells AbCheck unit for $6M Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial informa...
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior appro...
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR- wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort Follow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still aw...
2024-01-08 08:30:29 ET More on Affimed Affimed N.V. (AFMD) Q3 2023 Earnings Call Transcript Affimed N.V. 2023 Q3 - Results - Earnings Call Presentation Affimed sells AbCheck unit for $6M Affimed drops on plans to discontinue enrollment for cancer study cohort...
Dr. Adi Hoess to step down as CEO and Management Board Member Dr. Andreas Harstrick appointed Interim CEO Strategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025 Go forward organization will focus on advancing clinical programs Company confirms ...
2024-01-03 06:44:04 ET Immuno-oncology company Affimed ( NASDAQ: AFMD ) announced on Wednesday a deal to sell its wholly-owned subsidiary, AbCheck. Founded in 2009 as a spin-out of Affimed's antibody technology discovery unit, AbCheck discovers and optimizes human antibo...
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definit...
2023-12-19 09:08:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors...
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...